New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.

Since the beginning of the HIV epidemic, 84.1 million people have been diagnosed and 47% of those people have died because of the disease. At the end of 2021 there were 38.4 million people living with an HIV diagnosis. However, infection rates decreased by 25% from 2015 to 2020. It is important for pharmacists to be able to recognize the various pharmacologic options available for pre-exposure prophylaxis (PrEP). It is also important for pharmacists to be able to weigh the risks and benefits of the pharmacologic options to identify the most appropriate therapy for various individuals. Recently, cabotegravir an extended-release injectable suspension has become available. Since its release in March of 2022, many patients have been switched from oral therapy to cabotegravir. Some clinicians believe when transitioning patients from oral therapy to cabotegravir an overlap of the 2 therapies is needed, while others believe this is not necessary to maintain adequate protection. For the purposes of this presentation, literature surrounding the transition to cabotegravir will be explored, with an additional focus on the pharmacokinetics of intramuscular cabotegravir.